Related Experiment Video
Updated: May 21, 2026
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Glioblastoma: therapeutic challenges, what lies ahead
Flavia R S Lima1, Suzana Assad Kahn, Rossana C Soletti
1Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract:
Glioblastoma (GBM) is one of the most aggressive human cancers. Despite current advances in multimodality therapies, such as surgery, radiotherapy and chemotherapy, the outcome for patients with high grade glioma remains fatal. The knowledge of how glioma cells develop and depend on the tumor environment might open opportunities for new therapies. There is now a growing awareness that the main limitations in understanding and successfully treating GBM might be bypassed by the identification of a distinct cell type that has defining properties of somatic stem cells, as well as cancer-initiating capacity - brain tumor stem cells, which could represent a therapeutic target. In addition, experimental studies have demonstrated that the combination of antiangiogenic therapy, based on the disruption of tumor blood vessels, with conventional chemotherapy generates encouraging results. Emerging reports have also shown that microglial cells can be used as therapeutic vectors to transport genes and/or substances to the tumor site, which opens up new perspectives for the development of GBM therapies targeting microglial cells. Finally, recent studies have shown that natural toxins can be conjugated to drugs that bind to overexpressed receptors in cancer cells, generating targeted-toxins to selectively kill cancer cells. These targeted-toxins are highly effective against radiation- and chemotherapy-resistant cancer cells, making them good candidates for clinical trials in GBM patients. In this review, we discuss recent studies that reveal new possibilities of GBM treatment taking into account cancer stem cells, angiogenesis, microglial cells and drug delivery in the development of new targeted-therapies.
Insights
New glioblastoma (GBM) treatments focus on brain tumor stem cells, antiangiogenic therapy, microglial cells, and targeted toxins. These approaches offer new hope for overcoming fatal high-grade glioma outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Drug Discovery
Background:
- Glioblastoma (GBM) is a highly aggressive brain cancer with poor patient outcomes despite current treatments.
- Understanding the tumor microenvironment and identifying specific cell types are crucial for developing effective therapies.
- Brain tumor stem cells, angiogenesis, and microglial cells represent key areas for therapeutic intervention.
Purpose of the Study:
- To review recent advancements in glioblastoma treatment strategies.
- To explore novel therapeutic targets including cancer stem cells, angiogenesis, and microglial cells.
- To discuss the potential of targeted drug delivery systems, such as toxin conjugates, for glioblastoma therapy.
Main Methods:
- Review of current scientific literature on glioblastoma research.
- Analysis of studies focusing on cancer stem cells, antiangiogenic therapy, and microglial cell applications.
- Evaluation of research on targeted toxins and drug delivery mechanisms for cancer treatment.
Main Results:
- Brain tumor stem cells are identified as a potential therapeutic target.
- Antiangiogenic therapy combined with chemotherapy shows promising results.
- Microglial cells offer potential as vectors for targeted gene and substance delivery.
- Targeted toxins conjugated to drugs demonstrate high efficacy against resistant cancer cells.
Conclusions:
- New therapeutic avenues for glioblastoma involve targeting cancer stem cells and disrupting tumor angiogenesis.
- Utilizing microglial cells as therapeutic vectors and developing targeted toxins present innovative treatment possibilities.
- These emerging strategies hold promise for improving clinical trial outcomes in glioblastoma patients.
